These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18347427)

  • 41. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Local Delivery of OncoVEX
    Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
    Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
    [No Abstract]   [Full Text] [Related]  

  • 47. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
    Fukazawa T; Maeda Y; Matsuoka J; Ono T; Mominoki K; Yamatsuji T; Shigemitsu K; Morita I; Murakami I; Tanaka H; Durbin ML; Naomoto Y
    Anticancer Res; 2010 Dec; 30(12):4925-35. PubMed ID: 21187472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting gene-virotherapy of cancer and its prosperity.
    Liu XY
    Cell Res; 2006 Nov; 16(11):879-86. PubMed ID: 17102812
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.
    Zhou W; Dai S; Zhu H; Song Z; Cai Y; Lee JB; Li Z; Hu X; Fang B; He C; Huang X
    Gene Ther; 2017 Apr; 24(4):199-207. PubMed ID: 28075429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
    Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
    Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retargeted adenoviruses for radiation-guided gene delivery.
    Kaliberov SA; Kaliberova LN; Yan H; Kapoor V; Hallahan DE
    Cancer Gene Ther; 2016 Sep; 23(9):303-14. PubMed ID: 27492853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
    Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
    Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus.
    Gao H; Zhang X; Ding Y; Qiu R; Hong Y; Chen W
    Technol Cancer Res Treat; 2019; 18():1533033819853290. PubMed ID: 31138083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
    Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
    Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
    Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
    Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
    Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L
    J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.